Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 308-316

  Liu, Hong Mei ^a   Liu, Xue Feng ^a   Yao, Jin Long ^a   Wang, Chang Lin ^a   Yu, Ye ^a   Wang, Rui ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Key Laboratory of Preclinical Study for New Drugs of Gansu Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; ENDOMORPHIN 1; ENDORPHIN DERIVATIVE; GUANIDINOTYROSYL DEXTRO ALANYLTRYPTOPHYLPHENYLALANINAMIDE; GUANIDINOTYROSYL DEXTRO PROLYLGLYCYLTRYPTOPHYLPHENYLALANINAMIDE; GUANIDINOTYROSYLPROLYLTRYPTOPHYLPHENYLALANINAMIDE; MU OPIATE RECEPTOR; PEPTIDE DERIVATIVE; TYROSYL DEXTRO ALANYLTRYPTOPHYLPHENYLALANINAMIDE; UNCLASSIFIED DRUG;

ADDITION REACTION; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANALGESIA; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; FEMALE; HALOGENATION; LATENT PERIOD; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; BLOOD-BRAIN BARRIER; DRUG STABILITY; FEMALE; GUINEA PIGS; MALE; MICE; OLIGOPEPTIDES; PERMEABILITY; RADIOLIGAND ASSAY; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748996832     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.106484     Document Type: Article

References (34)

1. Abbruscato TJ, Williams SA, Misicka A, Lipkowski AS, Hruby VJ, and Davis TP (1996) Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. J Pharmacol Exp Ther 276:1049-1057.
2. Begley DJ (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48:136-146.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Brownless J and Williams CH (1993) Peptidases, peptides and the mammalian blood-brain barrier. J Neurochem 60:1089-1096.
5. Brownson EA, Abbruscato TJ, Gillespie TJ, Hruby VJ, and Davis TP (1994) Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J Pharmacol Exp Ther 270:675-680.
6. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Czapla MA, Gozal D, Alea OA, Beckerman RC, and Zadina JE (2000) Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am J Respir Crit Care Med 162:994-999.
8. Dooley CT, Chung NN, Wilks BC, Schiller PW, Bidlack JM, Pasternak GW, and Houghten RA (1994) An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science (Wash DC) 266:2019-2022.
9. Gao YF, Liu X, Wei J, Zhu BB, Chen Q, and Wang R (2005) Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett 15:1847-1850.
10. Gentry CL, Egleton RD, Gillespie T, Abbruscato TJ, Bechowski HB, Hruby VJ, and Davis TP (1999) The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides 20:1229-1238.
11. Gillespie TJ, Konings PN, Merrill BJ, and Davis TP (1992) A specific enzyme assay for aminopeptidase M in rat brain. Life Sci 51:2097-2106.
12. Habgood MD, Begley DJ, and Abbott NJ (2000) Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 20:231-253.
13. Haley TJ and McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 12:12-15.
14. Hau VS, Huber JD, Campos CR, Lipkowski AW, Misicka A, and Davis TP (2002) Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J Pharm Sci 91:2140-2149.
15. Janecka A, Kruszynski R, Fichna J, Kosson P, and Janecki T (2006) Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids. Peptides 27:131-135.
16. Kastin AJ, Fasold MB, Smith RR, Horner KA, and Zadina JE (2001) Saturable brain-to-blood transport of endomorphins. Exp Brain Res 139:70-75.
17. Kumagai AK, Eisenberg JB, and Pardridge WM (1987) Absorptive-mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. J Biol Chem 262:15214-15219.
18. Marastoni M, Salvadori S, Balboni G, Borea PA, Marzola G, and Tomatis R (1987) Synthesis and activity profiles of new dermorphin-(1-4) peptide analogues. J Med Chem 30:1538-1542.
19. α- amidino-Tyr-D-Arg-Phe-MeβAla-OH (ADAMB). J Med Chem 45:5081-5089.
20. 2, and examination of their opioid receptor binding activities and solution conformation. Biochem Biophys Res Commun 276:7-11.
21. Sanchez-Blanquez P, Rodriguez-Diaz M, DeAntonio I, and Garzon J (1999) Endomorphin-1 and endomorphin-2 show differences in their activation of μ opioid receptor-regulated G proteins in supraspinal antinociception in mice. J Pharmacol Exp Ther 291:12-18.
22. Schiller PW, Nguyen TM-D, Chung NN, and Lemieux C (1989) Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely high μ opioid receptor selectivity. J Med Chem 32:698-703.
23. Shane R, Wilk S, and Bodnar RJ (1999) Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815:278-286.
24. Shook JE, Pelton JT, Wire WS, Hirning LD, Hruby VJ, and Burks TF (1987) Pharmacologic evaluation of a cyclic somatostatin analog with antagonist activity at mu opioid receptors in vitro. J Pharmacol Exp Ther 240:772-777.
25. Simon J, Benyhe S, Abutidze K, Borsodi A, Szucs M, Tóth G, and Wollemann M (1986) Kinetics and physical parameters of rat brain opioid receptors solubilized by digitonin and CHAPS. J Neurochem 46:695-701.
26. Somogyvari-Vigh A, Kastin AJ, Liao J, Zadina JE, and Pan WH (2004) Endomorphins exit the brain by a saturable efflux system at the basolateral surface of cerebral endothelial cells. Exp Brain Res 156:224-230.
27. Temsamani J, Scherrmann JM, Rees AR, and Kaczorek M (2000) Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm Sci Technol Today 2:49-59.
28. Tömböly C, Péter A, and Tóth G (2002) In vitro quantitative study of the degradation of endomorphins. Peptides 23:1573-1580.
29. 5lenkephalin analogues with increased affinity and selectivity for delta opioid receptors. J Med Chem 33:249-253.
30. 5]enkephalin opioid analogs. J Pharmacol Exp Ther 266:1649-1655.
31. 5]enkephalin and two halogenated analogs after intravenous administration. J Pharmacol Exp Ther 259:1109-1117.
32. Wilson AM, Soignier RD, Zadina JE, Kastin AJ, Nores WL, Olson RD, and Olson GA (2000) Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 20:1871-1874.
33. Witt KA, Gillespie TJ, Huber JD, Egleton RD, and Davis TP (2001) Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22:2329-2343.
34. Zadina JE, Hackler L, Ge L-J, and Kastin AJ (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature (Lond) 386:499-502.